Molecular Mechanisms and Treatment of Brain Cancer: Recent Advances and Future Trends

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 208

Special Issue Editor

Special Issue Information

Dear Colleagues,

Brain cancer is a serious issue in the global burden of diseases. It is estimated that 3.24 million new cancer cases and 1.66 million cancer deaths will be registered across Europe in 2024 and 40,800 of these deaths are from brain and central nervous system (CNS) cancers. Despite extensive efforts in molecular biology research, advances in biomedical engineering, artificial intelligence (AI) and big data science, brain tumors remain among the deadliest forms of cancer, resisting almost all conventional and novel treatments.

The aim of this Special Issue is to focus on recent advances and trends in the diagnosis, treatment (standard and newly developed, as well as natural substances) and the development of new in vitro, in vivo or ex vivo models in the field of brain cancer. Original articles and reviews are welcome for publication on the topic.

Dr. Terezia Kiskova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain cancer
  • molecular mechanism
  • treatment
  • diagnosis
  • in vitro
  • in vivo
  • models

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop